Author | Andy Hahn, MD | OncLive

Author | Andy Hahn, MD

Articles

Dr. Hahn on Patients With Prostate Cancer Whom Neither Docetaxel or Abiraterone is an Option

September 11, 2018

Video

Andy Hahn, MD, a resident at the University of Utah School of Medicine, discusses therapy for patients with prostate cancer whom neither docetaxel or abiraterone acetate (Zytiga) is an option.

Dr. Hahn Discusses Abiraterone Versus Docetaxel in Prostate Cancer

June 27, 2018

Video

Andy Hahn, MD, resident, University of Utah School of Medicine, discusses abiraterone acetate (Zytiga) versus docetaxel in the treatment of patients with prostate cancer.

Dr. Hahn on Patient Selection for Abiraterone Versus Docetaxel in mHSPC

May 31, 2018

Video

Andy Hahn, MD, resident, University of Utah School of Medicine, discusses patient selection for abiraterone acetate (Zytiga) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC).

x